Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 8/20 | 0.55 |
| ▸ | RAB9A | P51151 | 7/20 | 0.55 |
| ▸ | MEN1 | O00255 | 7/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | FADS1 | O60427 | 1/20 | 0.48 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29368326 | 1.00 | STAT3 (0.64) | STAT3NPC1RAB9AMEN1KMT2A | |
| SCHEMBL15283269 | 0.85 | CYP1A2 (0.57) | STAT3NPC1RAB9AMEN1KMT2A | |
| SCHEMBL25143170 | 0.84 | RAB9A (0.57) | STAT3NPC1RAB9ARXFP1ALOX15 | |
| SCHEMBL30339193 | 0.84 | NPC1 (0.58) | STAT3NPC1RAB9AMEN1KMT2A | |
| SCHEMBL24072542 | 0.84 | NPC1 (0.58) | STAT3NPC1RAB9AMEN1KMT2A | |
| SCHEMBL30472740 | 0.83 | KCNMA1 (0.64) | STAT3MEN1KMT2AALOX15KCNMA1 | |
| SCHEMBL13524040 | 0.82 | STAT3 (0.64) | STAT3NPC1RAB9AMEN1KMT2A | |
| SCHEMBL16256828 | 0.82 | STAT3 (0.64) | STAT3NPC1RAB9AMEN1KMT2A | |
| SCHEMBL4756445 | 0.82 | STAT3 (0.60) | STAT3NPC1RAB9AMEN1KMT2A | |
| SCHEMBL23026966 | 0.81 | STAT3 (0.67) | STAT3NPC1RAB9AALOX15KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10814612-B2 | Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections | ROMARK LABORATORIES L.C. (US) | 2020-10-27 | — | — | US | claimed |
| EP-2709453-B1 | USE OF THIAZOLIDE COMPOUNDS FOR THE PREVENTION AND TREATMENT OF VIRAL DISEASES, CANCER AND DISEASES CAUSED BY INTRACELLULAR INFECTIONS | ROMARK LABORATORIES LC (US) | 2019-10-23 | — | — | EP | claimed |
| US-20190291404-A1 | USE OF THIAZOLIDE COMPOUNDS FOR THE PREVENTION AND TREATMENT OF VIRAL DISEASES, CANCER AND DISEASES CAUSED BY INTRACELLULAR INFECTIONS | ROMARK LABORATORIES L.C. (US) | 2019-09-26 | — | — | US | claimed |
| US-10336058-B2 | Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections | ROMARK LABORATORIES L.C. (US) | 2019-07-02 | — | — | US | claimed |
| US-20180126722-A1 | USE OF THIAZOLIDE COMPOUNDS FOR THE PREVENTION AND TREATMENT OF VIRAL DISEASES, CANCER AND DISEASES CAUSED BY INTRACELLULAR INFECTIONS | ROMARK LABORATORIES L.C. (US) | 2018-05-10 | — | — | US | claimed |
| CN-112480104-B | Nitrazonit derivative and medical application thereof | 绍兴君科臻元医药科技有限公司 | 2024-06-18 | — | — | CN | disclosed |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20230303504-A1 | CRYSTALLINE SALTS OF TIZOXANIDE AND 2-HYDROXY-N-(5-CHLORO-1,3-THIAZOL-2-YL)BENZAMIDE (RM-4848) WITH ETHANOLAMINE, MORPHOLINE, PROPANOLAMINE, PIPERAZINE AND N-METHYLPIPERAZINE | ROMARK LABORATORIES, L.C. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303504-A1 | CRYSTALLINE SALTS OF TIZOXANIDE AND 2-HYDROXY-N-(5-CHLORO-1,3-THIAZOL-2-YL)BENZAMIDE (RM-4848) WITH ETHANOLAMINE, MORPHOLINE, PROPANOLAMINE, PIPERAZINE AND N-METHYLPIPERAZINE | ROMARK LABORATORIES, L.C. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303504-A1 | CRYSTALLINE SALTS OF TIZOXANIDE AND 2-HYDROXY-N-(5-CHLORO-1,3-THIAZOL-2-YL)BENZAMIDE (RM-4848) WITH ETHANOLAMINE, MORPHOLINE, PROPANOLAMINE, PIPERAZINE AND N-METHYLPIPERAZINE | ROMARK LABORATORIES, L.C. (US) | 2023-09-28 | — | — | US | disclosed |
| WO-2017173056-A1 | THIAZOLIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | ROMARK LABORATORIES L.C. (US) | 2017-10-05 | — | — | WO | disclosed |
| US-20170281603-A1 | THIAZOLIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | ROMARK LABORATORIES L.C. (US) | 2017-10-05 | — | — | US | disclosed |
| WO-2017173056-A1 | THIAZOLIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | ROMARK LABORATORIES L.C. (US) | 2017-10-05 | — | — | WO | disclosed |
| US-20170281603-A1 | THIAZOLIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | ROMARK LABORATORIES L.C. (US) | 2017-10-05 | — | — | US | disclosed |
| US-20170281603-A1 | THIAZOLIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | ROMARK LABORATORIES L.C. (US) | 2017-10-05 | — | — | US | disclosed |
| EP-2709453-A1 | USE OF THIAZOLIDE COMPOUNDS FOR THE PREVENTION AND TREATMENT OF VIRAL DISEASES, CANCER AND DISEASES CAUSED BY INTRACELLULAR INFECTIONS | Romark Laboratories, L.C. (US) | 2014-03-26 | — | — | EP | disclosed |
| US-20120294831-A1 | USE OF THIAZOLIDE COMPOUNDS FOR THE PREVENTION AND TREATMENT OF VIRAL DISEASES, CANCER AND DISEASES CAUSED BY INTRACELLULAR INFECTIONS | ROMARK LABORATORIES L.C. | 2012-11-22 | — | — | US | disclosed |
| WO-2012158699-A1 | USE OF THIAZOLIDE COMPOUNDS FOR THE PREVENTION AND TREATMENT OF VIRAL DISEASES, CANCER AND DISEASES CAUSED BY INTRACELLULAR INFECTIONS | ROMARK LABORATORIES, L.C. (US) | 2012-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10814612-B2 | Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections | MAVS, NFATC1, HAVCR2 | STAT3 9/4885NPC1 148/4885RAB9A 340/4885 |
| US-10336058-B2 | Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections | MAVS, NFATC1, HAVCR2 | STAT3 9/4885NPC1 148/4885RAB9A 340/4885 |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, MDM2 | STAT3 3224/4885NPC1 3949/4885RAB9A 3280/4885 |
| US-20230303504-A1 | CRYSTALLINE SALTS OF TIZOXANIDE AND 2-HYDROXY-N-(5-CHLORO-1,3-THIAZOL-2-YL)BENZAMIDE (RM-4848) WITH ETHANOLAMINE, MORPHOLINE, PROPANOLAMINE, PIPERAZINE AND N-METHYLPIPERAZINE | SLC28A1, SLC28A2, NT5C | STAT3 2275/4885NPC1 401/4885RAB9A 2347/4885 |
| US-20120294831-A1 | USE OF THIAZOLIDE COMPOUNDS FOR THE PREVENTION AND TREATMENT OF VIRAL DISEASES, CANCER AND DISEASES CAUSED BY INTRACELLULAR INFECTIONS | NFATC1, MAVS, HAVCR2 | STAT3 11/4885NPC1 133/4885RAB9A 319/4885 |
| US-20170281603-A1 | THIAZOLIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | MAVS, TMPRSS4, TMPRSS11D | STAT3 280/4885NPC1 1653/4885RAB9A 1512/4885 |
| US-20190291404-A1 | USE OF THIAZOLIDE COMPOUNDS FOR THE PREVENTION AND TREATMENT OF VIRAL DISEASES, CANCER AND DISEASES CAUSED BY INTRACELLULAR INFECTIONS | NFATC1, MAVS, HAVCR2 | STAT3 11/4885NPC1 133/4885RAB9A 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.